Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study ; volume:147 ; number:3 ; day:19 ; month:9 ; year:2014 ; pages:599-607 ; date:10.2014
Breast cancer research and treatment ; 147, Heft 3 (19.9.2014), 599-607, 10.2014
- Urheber
-
Vici, Patrizia
Pizzuti, Laura
Natoli, Clara
Moscetti, Luca
Mentuccia, Lucia
Vaccaro, Angela
Sergi, Domenico
Lauro, Luigi Di
Trenta, Patrizia
Seminara, Patrizia
Santini, Daniele
Iezzi, Laura
Tinari, Nicola
Bertolini, Ilaria
Sini, Valentina
Mottolese, Marcella
Giannarelli, Diana
Giotta, Francesco
Maugeri-Saccà, Marcello
Barba, Maddalena
Marchetti, Paolo
Michelotti, Andrea
Sperduti, Isabella
Gamucci, Teresa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-014-3133-1
- URN
-
urn:nbn:de:101:1-2019102912183466961004
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vici, Patrizia
- Pizzuti, Laura
- Natoli, Clara
- Moscetti, Luca
- Mentuccia, Lucia
- Vaccaro, Angela
- Sergi, Domenico
- Lauro, Luigi Di
- Trenta, Patrizia
- Seminara, Patrizia
- Santini, Daniele
- Iezzi, Laura
- Tinari, Nicola
- Bertolini, Ilaria
- Sini, Valentina
- Mottolese, Marcella
- Giannarelli, Diana
- Giotta, Francesco
- Maugeri-Saccà, Marcello
- Barba, Maddalena
- Marchetti, Paolo
- Michelotti, Andrea
- Sperduti, Isabella
- Gamucci, Teresa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients